Oslo University Hospital, Oslo, Norway.
Regional Department for Eating Disorders, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Diabet Med. 2024 Sep;41(9):e15334. doi: 10.1111/dme.15334. Epub 2024 May 9.
Young women with type 1 diabetes are a high-risk population for eating disorders (ED). Prevention programs are lacking. In young women without diabetes, the Body Project has produced reductions in ED risk factors, ED symptoms and future ED onset. Therefore, the Body Project was adapted to type 1 diabetes, the Diabetes Body Project (DBP). In this protocol, we describe the multi-site randomized controlled trial (RCT) to evaluate efficacy of the DBP.
This is an ongoing RCT with four sites (Europe and US). In total 280, 14-35 year-old, women with type 1 diabetes ≥1 year and some level of body image concerns will be recruited in 2023. Participants are randomized to either virtual DBP groups or an educational control. The study constitutes 5 measurement points distributed over 2 years. The primary aim is to test if DBP will produce significantly greater reductions in ED behaviours, ED symptoms and future ED onset. The secondary aim is to test if DBP has significantly greater improvements in diabetes distress, quality of life and glycaemic outcomes.
We expect that DBP will be more efficacious in reducing ED behaviours, ED symptoms and ED onset compared to the control condition. Additionally, we hope to gain new knowledge on how DBP may affect diabetes-related outcomes.
If DBP proves efficacious, it has potential for immediate, clinical implementation at low-cost and may contribute to broad prevention of future ED onset among young women with type 1 diabetes.
NCT05399446.
患有 1 型糖尿病的年轻女性是饮食失调(ED)的高危人群。目前缺乏预防计划。在没有糖尿病的年轻女性中,“身体项目”已经减少了 ED 的风险因素、ED 症状和未来 ED 的发病。因此,“身体项目”被改编为 1 型糖尿病,即“糖尿病身体项目(DBP)”。在本方案中,我们描述了一项多地点随机对照试验(RCT),以评估 DBP 的疗效。
这是一项正在进行的 RCT,有四个地点(欧洲和美国)。总共将招募 280 名年龄在 14 至 35 岁之间、患有 1 型糖尿病≥1 年且存在一定程度身体意象问题的女性。参与者被随机分配到虚拟 DBP 组或教育对照组。该研究包括 5 个测量点,分布在 2 年。主要目的是测试 DBP 是否会显著减少 ED 行为、ED 症状和未来 ED 的发病。次要目的是测试 DBP 是否能显著改善糖尿病困扰、生活质量和血糖控制结果。
我们预计 DBP 在减少 ED 行为、ED 症状和 ED 发病方面将比对照组更有效。此外,我们希望获得关于 DBP 如何影响与糖尿病相关的结果的新知识。
如果 DBP 被证明有效,它具有立即在低成本下进行临床实施的潜力,并可能有助于广泛预防年轻 1 型糖尿病女性未来的 ED 发病。
NCT05399446。